Do you suffer from insulin demanding diabetes and wish you had a truly continuous, non-invasive blood glucose meter?


MecSense AS, based in Oslo Science Park, is developing a glucose sensor system, CNGI (Continuous Non invasive Glucose Indicator), that fulfils these requirements.


During summer 2021 starting June 1 they will conduct a pilot study approved by the the Norwegian Medicines Agency (Legemiddelverket), REK (Regional Ethical Committees, Regionale komiteer for medisinsk og helsefaglig forskningsetikk) and NPE (Norsk Pasientskadeerstatning, Norwegian System of Patient Injury Compensation) with endocrinologist, PhD Kari Anne Sveen as project manager. The study will take place at ShareLab, here in Oslo Science Park, under practical supervision of medical laboratory engineer Odd A. Odinsen.




MecSense's goal is to test their sensors on 10-20 individuals with type 1 diabetes requiring insulin treatment. Each participant must plan to set aside approximately 3 hours for each test round. The volunteers may choose to be tested only once or at several sessions over a period of time. The MecSense procedure only requires sensors to be attached to the body with medical grade double-sided tape and is completely non-invasive and consequently no penetration of the skin is needed. Food and drinks will be provided before each test-session if desired. Volunteers that meet the inclusion criteria will have to fill in a simple questionnaire and sign a written consent form before entering the study.  During the test session, the subjects will measure their blood sugar level every 10 minutes by Contour Next One glucose test which is used as comparative device in this study. If the participant also uses other continuous sensor such as Dexcom, Abbott Freestyle Libre or similar devices, these data should also be recorded.


If you are interested in participating in this study, please contact:


MecSense AS,

Odd A. Odinsen

Tel. 913 72 239